Search results for: Policy Analysis
Filter search results
New OHE Commission on Competition in the NHS
14 February 2011
…of Social Policy, London School of Economics Carol Propper, Professor of Economics, Imperial College and Bristol University Bob Ricketts, Director, Provider Policy, Department of Health Jon Sussex, Deputy Director, Office…
In Memoriam: George Teeling Smith, OHE’s First Director
17 February 2013
…would not exist but for George, nor would it have thrived for 50 years without his foresight in establishing OHE with the Policy Board and Editorial Board arrangement. Professor George…
The Market for Biosimilars: Evolution and Policy Options
1 November 2008
The authors point out that biopharmaceuticals are more complex agents than conventional chemical entities and therefore are more difficult to replicate after patent expiry. Off-patent versions of the originator product,…
OHE’s submission for the DHSC’s next 10 years of planning
9 December 2024
…we found that NICE’s severity modifier policy – although a welcome and well-intentioned evolution from its previous end-of-life policy – does not align with the levels at which the public…
Taking STRIDES: The value of diagnostics against AMR
10 June 2025
…policy, HTA, and procurement. Share this: Download publication Addressing a critical gap in AMR policy and evaluation Antimicrobial resistance (AMR) is a global health crisis, projected to cause up to…
Orphan Drugs Policies: A Suitable Case for Treatment
20 May 2014
…be clarified as the basis for policy revisions. The editorial is intended ‘not to provide complete solutions to all the policy problems, but rather to set out a roadmap whereby they…
Waiting Time Policies in the Health Sector: What Works?
27 October 2015
…13 OECD countries. He highlighted that the most common policy seems to be a form of maximum waiting time guarantee. Increasingly, such guarantees are backed with targets for providers and…
From STEDI to STRIDES: Valuing broader health-system benefits of AMR diagnostics
21 July 2025
…policy prioritisation Unlike antimicrobials, diagnostics are frequently omitted from AMR action plans, receiving less recognition from policymakers, compared to other interventions aimed at reducing antimicrobial use. Existing evidence gaps on…
Policy Options for Formulary Development in Middle-income Countries
1 January 2017
PhRMA commissioned OHE Consulting to explore options and recommend methods that could help middle-income countries efficiently and effectively identify medicines for formulary inclusion. This report presents a framework for developing…